Topic: Drug Prices

Donald Trump announces "Most Favored Nations" agreements aimed at slashing prescription drug prices by up to 600%. He claims the United States will no longer subsidize global drug costs, citing examples where $1,300 medications have dropped to $87. Trump criticizes mainstream media outlets like the New York Times for failing to report on these healthcare savings.

Donald Trump dismisses concerns about Greenland's self-determination, suggesting the residents will be "thrilled" once he speaks to them. He identifies his top three achievements as rebuilding the military (including the Iran/Venezuela operations), generating $18 trillion in business investment, and lowering drug prices through "Most Favored Nations" status.

Donald Trump is set to announce a drug price deal with Pfizer and launch a new "Trump RX" website. This follows significant financial losses for Pfizer and Moderna after billions in funding were redirected. While the deal is framed as a public relations win for Pfizer, the company remains criticized for its past actions regarding pharmaceutical products.

Gang members at an ICE facility reportedly barricaded themselves and threatened to take hostages, while Senator John Thune signaled plans to block an executive order regarding prescription drug pricing. The U.S. currently accounts for 74% of global pharmaceutical spending despite having a small fraction of the world population. The political class is accused of protecting corrupt pharmaceutical interests over the American middle class.

Robert F. Kennedy Jr. explains the Trump administration's plan to bring U.S. drug prices down to European levels by eliminating Pharmacy Benefit Managers (PBMs). He cites the example of Ozempic, which costs $1,300 in the U.S. but only $88 in London, as evidence of the pharmaceutical lobby's power. Kennedy asserts that the administration is prepared to take escalating steps if drug companies do not cooperate with the new executive orders.

Robert F. Kennedy Jr. reported meeting with the CEOs of the four largest pharmaceutical companies to discuss transitioning the U.S. from a "sick care" system to a true healthcare system. The discussion critiques the Affordable Care Act for creating incentives that encourage insurance and drug companies to keep care expensive. RFK Jr. claims these executives have committed to improving safety testing and lowering drug prices despite potential impacts on shareholder profits.